The Single-cell Omics Market size was estimated USD 1.5 billion in 2022 and is expected to reach USD 4.9 billion by 2030 at a CAGR of 16.2% during the forecast period of 2023-2030.
Single-cell omics is a new field of study that looks at individual cells to acquire a better knowledge of cellular processes, heterogeneity, and disease pathology. Technologies in this industry include single-cell genomics, transcriptomics, proteomics, and epigenomics.
For example, in October 2022, Illumina Inc., a pioneer in DNA sequencing and array-based technologies, and GenoScreen, a cutting-edge genomics company, announced a cooperation to accelerate the global campaign to eradicate tuberculosis (TB). As a result of the agreement, tuberculosis-affected countries will be better able to identify and treat drug-resistant tuberculosis (MDR-TB). This will help the World Health Organization's objective to end the global TB pandemic by 2035.
DRIVERS
Increasing demand for personalized medicine
Individual cell molecular analysis can provide crucial insights into disease causes, leading to more accurate and individualized treatments. Furthermore, rapid technological improvements have made single-cell omics more accessible and affordable. For example, owing of the development of high throughput sequencing technology, researchers can now examine hundreds of single cells at once, swiftly producing a large amount of data. Furthermore, because of their increasing prevalence, there is a greater interest in understanding the molecular pathways at the core of chronic diseases such as cancer and neurological problems. It provides researchers with a powerful tool for studying disease pathophysiology at the single-cell level.
Increasing Demand for Biologics
According to the FDA, the Center for Drug Evaluation and Research (CDER) approved 37 innovative pharmaceuticals in 2022, either as new molecular entities (NMEs) via New Drug Applications (NDAs) or as new therapeutic biological products via Biologics License Applications (BLAs). Single-cell omics can help with the selection and optimization of cell lines for biologics production.
RESTRAIN
Technical Difficulties
Complex processes and data processing approaches are required for single-cell omics analysis, which necessitates the use of powerful bioinformatics tools and computer resources. Single-cell technology adoption may be hampered by technical issues such as data integration and interpretation.
Moral Considerations
Privacy, informed consent, and the exploitation of human material are among ethical considerations raised by single-cell omics technologies. Addressing these challenges and putting in place regulatory frameworks are critical for the ethical use of single-cell omics data.
OPPORTUNITY
The creation of new diagnostic tests and medicines
Biomarkers for illness diagnosis, prognosis, and therapy response can be identified using single-cell omics. This could pave the way for novel diagnostic tests and medicines. Single-cell omics can aid in the discovery of new therapeutic targets and pathways, as well as the evaluation of medication efficacy and toxicity. This could result in the development of more effective and safer medications. Single-cell omics can assist increase crop output and quality while also improving food safety and traceability. This could lead to more secure and sustainable food systems.
CHALLENGES
The Technique of Single-Cell Omics Is Expensive
Specialized equipment, reagents, and data analytic resources are required, which raises the entire cost. The affordability and cost-effectiveness of single-cell omics technologies are critical considerations for their wider adoption, particularly in resource-constrained contexts or for small research institutes.
Technical Complications Associated with the Research • Lack of Standardized Protocols and Benchmark Datasets.
It is becoming increasingly challenging to keep active cancer trial locations in Ukraine. To maintain the validity of clinical trial results, a regulated and consistent environment must be in place across foreign sites. Ukraine and Russia make substantial contributions to worldwide cancer clinical research. The impact of Ukraine's conflict on clinical trials may vary, but will primarily be related to the closure of treatment facilities, internal displacement, and forced migration. The conflict is also expected to have an impact on the contribution of Russian clinical trial sites. All clinical investigations are planned around specific time points to allow for unambiguous and uniform data gathering and analysis. There is no information available on the number of local and international clinical trials that may be threatened in the two nations currently involved in this conflict (Ukraine and Russia). The purpose of this narrative study was to explain the current landscape of systemic cancer clinical trials in Ukraine and Russia, as well as to estimate how many cancer clinical trials are in jeopardy due to the conflict.
By Product Type
Single-Cell Genomics
Single-Cell Transcriptomics
Single-Cell Proteomics
Single-Cell Metabolomics
In 2022, the single-cell Genomics segment is expected to held the highest market share of 45.9% during the forecast period due to the factors such as the rising demand from a diverse variety of end-users, prospective therapeutic uses of single-cell genomics platforms, and technological improvements. Microfluidics, high-throughput sequencing tools, and droplet-based approaches enabled researchers to examine cellular heterogeneity at unprecedented resolution.
By Application
Oncology
Cell Biology
Neurology
Immunology
In 2022, the oncology segment is expected to dominate the market growth of 55.2% during the forecast period. The rising worldwide cancer burden, rapid innovation of single-cell analysis techniques, and rising usage of omics-based tools to research cancer progression are expected to support a large segment market share.
By End User
Pharmaceutical & Biotechnology Companies
Academic and Research Organizations
Hospital and Diagnostic Laboratories
Others
.png)
In 2022, the academic and research organizations segment is expected to dominate the market growth of 42.9% during the forecast period. The increasing use of technology on college campuses, increased research efforts to develop novel modeling tools, and increased research investigations by various research institutes to investigate multiple applications of cellular biology are expected to fuel segment expansion. Furthermore, researchers are investigating several applications of single-cell technologies in domains such as transcriptomics, genomics, proteomics, epigenomics, and metabolomics. Schmidt Futures, for example, gave USD 550 million to a new research facility focused on creating single-cell proteomics technologies in March 2023.
North America held a significant market share of 46.4% in 2022. Several market participants' presence and varied innovations are some of the primary drivers driving regional growth. Furthermore, the existence of advanced healthcare and increasing R&D activities for the development of breakthrough technologies are driving the regional market. Furthermore, favorable government regulations, the expanding importance of cellular therapies, and the growing tendency toward precision medicine are bolstering the regional industry. For example, the United States has launched the Precision Medicine Initiative to enhance health and treat ailments.
Asia-Pacific is witness to expand fastest CAGR rate of 17.8% during the forecast The region's single-cell omics market is expected to be driven by factors such as the increasing burden of target illness and increased need for enhanced therapies. The growing interest of market players in capturing untapped market potential, as well as their increasing investments in the region, is enabling the region's market expansion. Furthermore, expanding agreements among organizations to strengthen their market outlets is another possible element driving the regional market. For example, Mission Bio and SequMed entered a deal in December 2021 that allowed Mission Bio to utilize its offerings in China.
REGIONAL COVERAGE
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are Danaher Corporation, CYTENA GmbH, 10x Genomics, BD, CELLENION, PerkinElmer Inc., ANGLE plc, Illumina, Inc., Bio-Rad Laboratories, Inc., Mission Bio, Standard Bio Tools Inc., and Others.
In February 2023, BD unveiled a new single-cell multi-omics analysis tool. It enables researchers to conduct high-throughput investigations without jeopardizing sample integrity, potentially speeding up the pace of discovery in a wide range of domains.
In June 2021, CellenCHIP 384 for single-cell omics sample preparation has been released by SCIENION and Cellenion as a consumable in the new cellenCHIP 384 - 3'RNA-seq Kit for scalable, nanoliter volume library development of single cells.
|
Report Attributes |
Details |
|
Market Size in 2022 |
US$ 1.5 billion |
|
Market Size by 2030 |
US$ 4.9 billion |
|
CAGR |
CAGR of 16.2% From 2023 to 2030 |
|
Base Year |
2022 |
|
Forecast Period |
2023-2030 |
|
Historical Data |
2019-2021 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
By Product Type (Single-Cell Genomics, Single-Cell Transcriptomics, Single-Cell Proteomics, Single-Cell Metabolomics), By Application (Oncology, Cell Biology, Neurology, Immunology), By End User (Pharmaceutical & Biotechnology Companies, Academic and Research Organizations, Hospital and Diagnostic Laboratories, Others) |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
|
Company Profiles |
Danaher Corporation, CYTENA GmbH, 10x Genomics, BD, CELLENION, PerkinElmer Inc., ANGLE plc, Illumina, Inc., Bio-Rad Laboratories, Inc., Mission Bio, Standard Bio Tools Inc. |
|
Key Drivers |
•Increasing demand for personalized medicine •Increasing Demand for Biologics |
|
Market Restrain |
•Technical Difficulties •Moral Considerations |
Increasing demand for personalized medicine and rising demand for biologics.
The growth rate of Single-cell Omics market is expected to grow USD 4.9 billion by 2030.
Single-cell Omics market size was valued at USD 1.5 billion in 2022.
Single-cell Omics market is anticipated to expand by 16.2% from 2023 to 2030.
North America segment is expected to held the highest market share of 46.4% in 2022.
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Single-cell Omics Market Segmentation, By Product Type
8.1 Single-Cell Genomics
8.2 Single-Cell Transcriptomics
8.3 Single-Cell Proteomics
8.4 Single-Cell Metabolomics
9. Single-cell Omics Market Segmentation, By Application
9.1 Oncology
9.2 Cell Biology
9.3 Neurology
9.4 Immunology
10. Single-cell Omics Market Segmentation, By End User
10.1 Pharmaceutical & Biotechnology Companies
10.2 Academic and Research Organizations
10.3 Hospital and Diagnostic Laboratories
10.4 Others
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Single-cell Omics Market by Country
11.2.2North America Single-cell Omics Market by Product Type
11.2.3 North America Single-cell Omics Market by Application
11.2.4 North America Single-cell Omics Market by End User
11.2.5 USA
11.2.5.1 USA Single-cell Omics Market by Product Type
11.2.5.2 USA Single-cell Omics Market by Application
11.2.5.3 USA Single-cell Omics Market by End User
11.2.6 Canada
11.2.6.1 Canada Single-cell Omics Market by Product Type
11.2.6.2 Canada Single-cell Omics Market by Application
11.2.6.3 Canada Single-cell Omics Market by End User
11.2.7 Mexico
11.2.7.1 Mexico Single-cell Omics Market by Product Type
11.2.7.2 Mexico Single-cell Omics Market by Application
11.2.7.3 Mexico Single-cell Omics Market by End User
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Single-cell Omics Market by Country
11.3.1.2 Eastern Europe Single-cell Omics Market by Product Type
11.3.1.3 Eastern Europe Single-cell Omics Market by Application
11.3.1.4 Eastern Europe Single-cell Omics Market by End User
11.3.1.5 Poland
11.3.1.5.1 Poland Single-cell Omics Market by Product Type
11.3.1.5.2 Poland Single-cell Omics Market by Application
11.3.1.5.3 Poland Single-cell Omics Market by End User
11.3.1.6 Romania
11.3.1.6.1 Romania Single-cell Omics Market by Product Type
11.3.1.6.2 Romania Single-cell Omics Market by Application
11.3.1.6.4 Romania Single-cell Omics Market by End User
11.3.1.7 Turkey
11.3.1.7.1 Turkey Single-cell Omics Market by Product Type
11.3.1.7.2 Turkey Single-cell Omics Market by Application
11.3.1.7.3 Turkey Single-cell Omics Market by End User
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Single-cell Omics Market by Product Type
11.3.1.8.2 Rest of Eastern Europe Single-cell Omics Market by Application
11.3.1.8.3 Rest of Eastern Europe Single-cell Omics Market by End User
11.3.2 Western Europe
11.3.2.1 Western Europe Single-cell Omics Market by Product Type
11.3.2.2 Western Europe Single-cell Omics Market by Application
11.3.2.3 Western Europe Single-cell Omics Market by End User
11.3.2.4 Germany
11.3.2.4.1 Germany Single-cell Omics Market by Product Type
11.3.2.4.2 Germany Single-cell Omics Market by Application
11.3.2.4.3 Germany Single-cell Omics Market by End User
11.3.2.5 France
11.3.2.5.1 France Single-cell Omics Market by Product Type
11.3.2.5.2 France Single-cell Omics Market by Application
11.3.2.5.3 France Single-cell Omics Market by End User
11.3.2.6 UK
11.3.2.6.1 UK Single-cell Omics Market by Product Type
11.3.2.6.2 UK Single-cell Omics Market by Application
11.3.2.6.3 UK Single-cell Omics Market by End User
11.3.2.7 Italy
11.3.2.7.1 Italy Single-cell Omics Market by Product Type
11.3.2.7.2 Italy Single-cell Omics Market by Application
11.3.2.7.3 Italy Single-cell Omics Market by End User
11.3.2.8 Spain
11.3.2.8.1 Spain Single-cell Omics Market by Product Type
11.3.2.8.2 Spain Single-cell Omics Market by Application
11.3.2.8.3 Spain Single-cell Omics Market by End User
11.3.2.9 Netherlands
11.3.2.9.1 Netherlands Single-cell Omics Market by Product Type
11.3.2.9.2 Netherlands Single-cell Omics Market by Application
11.3.2.9.3 Netherlands Single-cell Omics Market by End User
11.3.2.10 Switzerland
11.3.2.10.1 Switzerland Single-cell Omics Market by Product Type
11.3.2.10.2 Switzerland Single-cell Omics Market by Application
11.3.2.10.3 Switzerland Single-cell Omics Market by End User
11.3.2.11. Austria
11.3.2.11.1 Austria Single-cell Omics Market by Product Type
11.3.2.11.2 Austria Single-cell Omics Market by Application
11.3.2.11.3 Austria Single-cell Omics Market by End User
11.3.2.12 Rest of Western Europe
11.3.2.12.1 Rest of Western Europe Single-cell Omics Market by Product Type
11.3.2.12.2 Rest of Western Europe Single-cell Omics Market by Application
11.3.2.12.3 Rest of Western Europe Single-cell Omics Market by End User
11.4 Asia-Pacific
11.4.1 Asia-Pacific Single-cell Omics Market by Country
11.4.2 Asia-Pacific Single-cell Omics Market by Product Type
11.4.3 Asia-Pacific Single-cell Omics Market by Application
11.4.4 Asia-Pacific Single-cell Omics Market by End User
11.4.5 China
11.4.5.1 China Single-cell Omics Market by Product Type
11.4.5.2 China Single-cell Omics Market by Application
11.4.5.3 China Single-cell Omics Market by End User
11.4.6 India
11.4.6.1 India Single-cell Omics Market by Product Type
11.4.6.2 India Single-cell Omics Market by Application
11.4.6.3 India Single-cell Omics Market by End User
11.4.7 Japan
11.4.7.1 Japan Single-cell Omics Market by Product Type
11.4.7.2 Japan Single-cell Omics Market by Application
11.4.7.3 Japan Single-cell Omics Market by End User
11.4.8 South Korea
11.4.8.1 South Korea Single-cell Omics Market by Product Type
11.4.8.2 South Korea Single-cell Omics Market by Application
11.4.8.3 South Korea Single-cell Omics Market by End User
11.4.9 Vietnam
11.4.9.1 Vietnam Single-cell Omics Market by Product Type
11.4.9.2 Vietnam Single-cell Omics Market by Application
11.4.9.3 Vietnam Single-cell Omics Market by End User
11.4.10 Singapore
11.4.10.1 Singapore Single-cell Omics Market by Product Type
11.4.10.2 Singapore Single-cell Omics Market by Application
11.4.10.3 Singapore Single-cell Omics Market by End User
11.4.11 Australia
11.4.11.1 Australia Single-cell Omics Market by Product Type
11.4.11.2 Australia Single-cell Omics Market by Application
11.4.11.3 Australia Single-cell Omics Market by End User
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Single-cell Omics Market by Product Type
11.4.12.2 Rest of Asia-Pacific Single-cell Omics Market by Application
11.4.12.3 Rest of Asia-Pacific Single-cell Omics Market by End User
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Single-cell Omics Market by Country
11.5.1.2 Middle East Single-cell Omics Market by Product Type
11.5.1.3 Middle East Single-cell Omics Market by Application
11.5.1.4 Middle East Single-cell Omics Market by End User
11.5.1.5 UAE
11.5.1.5.1 UAE Single-cell Omics Market by Product Type
11.5.1.5.2 UAE Single-cell Omics Market by Application
11.5.1.5.3 UAE Single-cell Omics Market by End User
11.5.1.6 Egypt
11.5.1.6.1 Egypt Single-cell Omics Market by Product Type
11.5.1.6.2 Egypt Single-cell Omics Market by Application
11.5.1.6.3 Egypt Single-cell Omics Market by End User
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Single-cell Omics Market by Product Type
11.5.1.7.2 Saudi Arabia Single-cell Omics Market by Application
11.5.1.7.3 Saudi Arabia Single-cell Omics Market by End User
11.5.1.8 Qatar
11.5.1.8.1 Qatar Single-cell Omics Market by Product Type
11.5.1.8.2 Qatar Single-cell Omics Market by Application
11.5.1.8.3 Qatar Single-cell Omics Market by End User
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Single-cell Omics Market by Product Type
11.5.1.9.2 Rest of Middle East Single-cell Omics Market by Application
11.5.1.9.3 Rest of Middle East Single-cell Omics Market by End User
11.5.2 Africa
11.5.2.1 Africa Transfusion Diagnostics Market by Country
11.5.2.2 Africa Single-cell Omics Market by Product Type
11.5.2.3 Africa Single-cell Omics Market by Application
11.5.2.4 Africa Single-cell Omics Market by End User
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Single-cell Omics Market by Product Type
11.5.2.5.2 Nigeria Single-cell Omics Market by Application
11.5.2.5.3 Nigeria Single-cell Omics Market by End User
11.5.2.6 South Africa
11.5.2.6.1 South Africa Single-cell Omics Market by Product Type
11.5.2.6.2 South Africa Single-cell Omics Market by Application
11.5.2.6.3 South Africa Single-cell Omics Market by End User
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Single-cell Omics Market by Product Type
11.5.2.7.2 Rest of Africa Single-cell Omics Market by Application
11.5.2.7.3 Rest of Africa Single-cell Omics Market by End User
11.6 Latin America
11.6.1 Latin America Single-cell Omics Market by Country
11.6.2 Latin America Single-cell Omics Market by Product Type
11.6.3 Latin America Single-cell Omics Market by Application
11.6.4 Latin America Single-cell Omics Market by End User
11.6.5 Brazil
11.6.5.1 Brazil Single-cell Omics Market by Product Type
11.6.5.2 Brazil Single-cell Omics Market by Application
11.6.5.3 Brazil Single-cell Omics Market by End User
11.6.6 Argentina
11.6.6.1 Argentina Single-cell Omics Market by Product Type
11.6.6.2 Argentina Single-cell Omics Market by Application
11.6.6.3 Argentina Single-cell Omics Market by End User
11.6.7 Colombia
11.6.7.1 Colombia Single-cell Omics Market by Product Type
11.6.7.2 Colombia Single-cell Omics Market by Application
11.6.7.3 Colombia Single-cell Omics Market by End User
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Single-cell Omics Market by Product Type
11.6.8.2 Rest of Latin America Single-cell Omics Market by Application
11.6.8.3 Rest of Latin America Single-cell Omics Market by End User
12 Company profile
12.1 Danaher Corporation
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Product/ Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 CYTENA GmbH
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 10x Genomics
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 BD
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 CELLENION
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 PerkinElmer Inc.
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 ANGLE plc
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Illumina, Inc.
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Product/Services Offered
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Bio-Rad Laboratories, Inc.
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services Offered
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Mission Bio
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services Offered
12.10.4 SWOT Analysis
12.10.5 The SNS View
12.11 Standard Bio Tools Inc.
12.11.1 Company Overview
12.11.2 Financials
12.11.3 Product/Services Offered
12.11.4 SWOT Analysis
12.11.5 The SNS View
13. Competitive Landscape
13.1 Competitive Bench marking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Electronic Trial Master File (eTMF) Systems Market Size was valued at USD 1.43 billion in 2022, and is expected to reach USD 3.78 billion by 2030 and grow at a CAGR of 12.9% over the forecast period 2023-2030.
The Wearable Medical Devices Market is expected to reach USD 210.66 billion by 2031, and its Size was valued at USD 33.8 billion in 2023, it grows at a CAGR of 25.7% over the forecast period 2024-2031.
The Digital Diabetes Management Market size was estimated USD 12.053 billion in 2022 and is expected to reach USD 22.47 billion by 2030 at a CAGR of 8.1% during the forecast period of 2023-2030.
The NLP in Healthcare and Life Sciences Market Size was valued at USD 2.35 billion in 2022 and is expected to reach USD 9.54 billion by 2030, and grow at a CAGR of 19.1% over the forecast period 2023-2030.
The Degenerative Disc Disease Treatment Market size was valued at USD 30.32 billion in 2023 and is estimated to reach at USD 55.75 billion in 2031 and grow at a compound annual growth rate approx. CAGR of 7.91% predicted for the forecast period of 2024-20
The Protein A Resin Market, size was estimated USD 1.4 billion in 2022 and is expected to reach USD 2.97 billion by 2030 at a CAGR of 9.9% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
